Archive — US — techcrunch
Why investors just bet $85M on this Indian company’s generic drug strategy
Truemeds, an Indian startup focusing on affordable generic drugs, raised $85M, raising its valuation to over $400M. Differentiating from competitors, Truemeds helps patients switch to lower-cost alternatives. The company has seen a 66% revenue increase and serves 500,000 customers monthly, aiming to expand into diagnostics. Investors see promise in its unique strategy amid a crowded market.
Key points
- Truemeds raised $85 million, with $65 million in primary and $20 million in secondary funding.
- Valuation increased from $110 million to over $400 million.
- Focus on generic substitutes addresses affordability, catering to over 400 million chronic patients in India.
- Achieved 66% revenue growth to $57 million in the last financial year, with 3 million customers to date.
- Distinct approach includes increasing average discounts from 29% to 32%, while competitors reduced theirs.
- Plans to develop AI systems for customized patient interactions and expand diagnostics offerings.
Why it matters
- In 2023, the growth of telemedicine and e-pharmacies highlights the trend towards digital health solutions.
- Rising healthcare costs and a push for affordable medication resonate with global healthcare challenges.
- Other startups worldwide are exploring similar models of combining technology with healthcare to enhance patient access.
Truemeds stands out in India's competitive online pharmacy market by emphasizing affordability through generics, securing significant investment and showing robust growth, while seeking to innovate further into diagnostics and AI-driven solutions.